HBM Healthcare Investments Aktie
WKN: 984345 / ISIN: CH0012627250
|
08.12.2025 14:50:43
|
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics for up to USD 820 million
|
HBM Healthcare Investments AG
/ Key word(s): Acquisition/Partnership
HBM Healthcare Investments, an investment company focused on the healthcare sector, announces that the shareholders of its privately held portfolio company Bluejay Therapeutics have approved a takeover by Mirum Pharmaceuticals (Nasdaq: MIRM). Under the terms of the definitive agreement, Mirum has agreed to acquire all outstanding shares of Bluejay for USD 250 million in cash and USD 370 million in Mirum common stock, plus potential tiered sales-based milestone payments of up to USD 200 million in cash. HBM Healthcare Investments invested USD 7 million into the Series C financing round of Bluejay Therapeutics in May 2024. Upon completion of the transaction, HBM Healthcare Investments will receive approximately USD 6 million in cash and Mirum Pharmaceuticals shares currently valued at USD 7 million. Additional payments of up to USD 3.7 million may be received in the future upon the achievement of the sales-based milestones. Bluejay Therapeutics develops therapies for viral and liver diseases. The company is testing brelovitug, an antibody for the treatment of chronic hepatitis D and hepatitis B viral infections. Contact
End of Media Release |
| Language: | English |
| Company: | HBM Healthcare Investments AG |
| Bundesplatz 1 | |
| 6300 Zug | |
| Switzerland | |
| Phone: | +41438887171 |
| Fax: | +41438887172 |
| E-mail: | info@hbmhealthcare.com |
| Internet: | https://www.hbmhealthcare.com |
| ISIN: | CH0012627250 |
| Valor: | 1262725 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 2241904 |
| End of News | EQS News Service |
|
|
2241904 08.12.2025 CET/CEST
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu HBM Healthcare Investments AGmehr Nachrichten
|
08.12.25 |
Mirum Pharmaceuticals übernimmt HBM Portfoliounternehmen Bluejay Therapeutics für bis zu USD 820 Millionen (EQS Group) | |
|
08.12.25 |
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics for up to USD 820 million (EQS Group) | |
|
01.12.25 |
Key Figures 30.11.2025 (EQS Group) | |
|
17.11.25 |
Key Figures 15.11.2025 (EQS Group) | |
|
03.11.25 |
Key Figures 31.10.2025 (EQS Group) | |
|
24.10.25 |
HBM Healthcare Investments publishes Half-Year Report as at 30 September 2025 with key figures for the first six months of the 2025/2026 financial year (EQS Group) | |
|
24.10.25 |
HBM Healthcare Investments publiziert Halbjahresbericht per 30. September 2025 mit Kennzahlen für die ersten sechs Monate des Geschäftsjahrs 2025/2026 (EQS Group) | |
|
16.10.25 |
Key Figures 15.10.2025 (EQS Group) |
Analysen zu HBM Healthcare Investments AGmehr Analysen
Aktien in diesem Artikel
| HBM Healthcare Investments AG | 219,50 | 0,23% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.